Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement

Pathologic evaluation of early breast cancer after neoadjuvant therapy is essential to provide prognostic information based on tumor response to treatment (pathologic complete response [pCR] or non-pCR) and to inform therapy decisions after surgery. To harmonize the pathologist’s handling of surgica...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2022-06, Vol.108 (3), p.196-203
Main Authors: Guerini-Rocco, Elena, Botti, Gerardo, Foschini, Maria Pia, Marchiò, Caterina, Mastropasqua, Mauro Giuseppe, Perrone, Giuseppe, Roz, Elena, Santinelli, Alfredo, Sassi, Isabella, Galimberti, Viviana, Gianni, Luca, Viale, Giuseppe
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pathologic evaluation of early breast cancer after neoadjuvant therapy is essential to provide prognostic information based on tumor response to treatment (pathologic complete response [pCR] or non-pCR) and to inform therapy decisions after surgery. To harmonize the pathologist’s handling of surgical specimens after neoadjuvant therapy, a panel of experts in breast cancer convened to developed a consensus on six main topics: (1) definition of pCR, (2) required clinical information, (3) gross examination and sampling, (4) microscopic examination, (5) evaluation of lymph node status, and (6) staging of residual breast tumor. The resulting consensus statements reported in this document highlight the role of an accurate evaluation of tumor response and define the minimum requirements to standardize the assessment of breast cancer specimens after neoadjuvant therapy.
ISSN:0300-8916
2038-2529
DOI:10.1177/03008916211062642